Practice
Featured experience
FTC clearance of Novo Nordisk acquisition of certain Catalent sites
We secured regulatory approval following a lengthy review
Syngenta antitrust litigation victory
We secured the dismissal of a price-fixing antitrust suit
Favorable plea deal for paving company in bid-rigging case
We represented the defendant in a DOJ antitrust investigation, securing a favorable plea deal
Antitrust advice to AI company
We are advising our client on a range of antitrust issues
Comcast subsidiary FreeWheel acquires BeeswaxIO
Davis Polk is advising FreeWheel, a subsidiary of Comcast Corporation, on its acquisition of BeeswaxIO Corporation…
IHS Markit investment in Gen II Fund Services
Davis Polk advised IHS Markit in connection with its investment in Gen II Fund Services, LLC. The strategic investment was…
Murphy USA $645 million acquisition of QuickChek
Davis Polk is advising Murphy USA on its $645 million acquisition of QuickChek Corporation. The transaction is expected to…
Ingram Micro $7.2 billion acquisition by Platinum Equity
Davis Polk is advising Ingram Micro Inc. on its $7.2 billion acquisition by Platinum Equity from HNA Technology Co., Ltd, a…
IHS Markit $44 billion merger with S&P Global
Davis Polk is advising IHS Markit on its all-stock merger with S&P Global that values IHS Markit at an enterprise value…
Favorable decision in Comcast antitrust litigation
We represent Comcast in antitrust litigation brought by Altitude Sports & Entertainment, a Denver regional sports…
Coloplast acquisition of Nine Continents Medical
Davis Polk advised Coloplast on its acquisition of Nine Continents Medical, an early stage company pioneering an implantable…
Assurant acquisition of HYLA Mobile
Davis Polk is advising Assurant on its acquisition of mobile device trade-in innovator HYLA Mobile. The transaction is…
Morgan Stanley $7 billion acquisition of Eaton Vance
Davis Polk is advising Morgan Stanley on its $7 billion acquisition of Eaton Vance Corp. The acquisition is subject to…
Gilead Sciences $21 billion acquisition of Immunomedics
Davis Polk is advising Gilead Sciences, Inc. in its acquisition of Immunomedics, Inc. for $88.00 per share in cash. The…